RGLS (Regulus Therapeutics Inc.) Stock Price

Regulus Therapeutics (RGLS) develops cutting-edge RNA-based drugs for the therapy of renal pathologies, minimizing risks through collaborations with major market players. This price chart, where the indicator stands at 8.17, confirms that the secondary offering is priced in while the market awaits the results of Phase 2 trials for polycystic kidney disease. Currently, Regulus Therapeutics (RGLS) lacks pricing power; however, success in treating rare mutations will grant the company monopolist status.

Price Chart: Regulus Therapeutics (RGLS) for 07/04/2022 - 07/05/2025

Regulus Therapeutics, Inc. (RGLS) - metric breakdowns and financial figures

- stock value and consensus price forecast:

Price Chart Regulus Therapeutics|RGLS - Fair Value Consensus

- business market valuation indicators:

Market Capitalization Regulus Therapeutics, Inc.|RGLS - Full Takeover Company Value

- book capitalization information:

Net Assets per Single Share Regulus Therapeutics|RGLS - Company Book Value|Market Value to Book Value Ratio regulusrx.com|RGLS - Company Total Asset Base

- debt and liquidity data:

- company profitability and valuation multiples indicators:

RGLS - Company Net Income|Projected Future Earnings Regulus Therapeutics|RGLS - Market Cap to Net Income Ratio|Projected Price to Earnings Regulus Therapeutics Inc.|RGLS - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Regulus Therapeutics, Inc.|RGLS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Regulus Therapeutics|RGLS - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months regulusrx.com|RGLS - Expected net earnings per share growth this year|Expected earnings per share growth for next year Regulus Therapeutics

Summary company analytics:Regulus Therapeutics

The price reflects the market consensus on the asset's value, allowing investors to assess volatility and determine optimal entry points based on the market's reaction to news. Analyzing the price history of Regulus Therapeutics (RGLS), it is evident that the valuation trend is independent of macroeconomic cycles or inflation, as progress in RNA therapy development is driven exclusively by clinical trial results.

Analysis of competing companies